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Feglymycin (FGM), a natural Streptomyces-derived 13mer peptide, consistently inhibits HIV replication
in the lower mM range. FGM also inhibits HIV cell-to-cell transfer between HIV-infected T cells and
uninfected CD4þ T cells and the DC-SIGN-mediated viral transfer to CD4þ T cells. FGM potently
interacts with gp120 (X4 and R5) as determined by SPR analysis and shown to act as a gp120/CD4
binding inhibitor. Alanine-scan analysis showed an important role for L-aspartic acid at position 13 for
its anti-HIV activity. In vitro generated FGM-resistant HIV-1 IIIB virus (HIV-1 IIIBFGMres) showed two
unique mutations in gp120 at positions I153L and K457I. HIV-1 IIIBFGMres virus was equally susceptible
to other viral binding/adsorption inhibitors with the exception of dextran sulfate (9-fold resistance) and
cyclotriazadisulfonamide (415-fold), two well-described compounds that interfere with HIV entry. In
conclusion, FGM is a unique prototype lead peptide with potential for further development of more
potent anti-HIV derivatives.
& 2012 Elsevier Inc. All rights reserved.Introduction
Despite enormous costs on effective HIV/AIDS prevention cam-
paigns, every day more than 7000 novel human immunodeﬁciency
virus (HIV) infections are occurring and approximately 34 million
people are estimated to live with HIV in 2011 (http://www.who.
int/hiv/data/en/index.html). Although there are already more than
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leuven.be (D. Schols).(ARV) drugs, HIV resistance to these ARV drugs has raised to high
levels. Therefore, continued efforts in discovering new drugs and
developing new HIV prevention methods (e.g., microbicides) are
still needed. An interesting target for HIV drug development is still
the HIV entry pathway. HIV entry into its target cells starts with
the binding of the heavy glycosylated envelope protein, gp120,
with the cellular CD4 receptor resulting in conformational changes
inside the viral envelope for subsequent interactions with the
chemokine receptors CCR5 and/or CXCR4. Interaction of gp120
with these HIV co-receptors results in insertion of gp41 into the
target membrane and formation of the hairpin structure necessary
for membrane fusion (Tilton and Doms, 2010).
At present, enfuvirtide (T20, Fuzeons) is the only licensed
peptidic HIV entry fusion inhibitor. This synthetic peptide of 36
amino acids interacts with the heptad repeat 1 (HR1) domain
region of gp41 and inhibits the hairpin structure formation
necessary for virus-cell fusion (Matthews et al., 2004). It is self-
administered twice daily subcutaneously in patients infected with
multidrug resistant HIV-1 (Joly et al., 2010). Due to its unique
mechanism of action, no cross-resistance with other ARV drugs has
been observed (Matthews et al., 2004). Novel generations of HIV-1
fusion inhibitory peptides with more potent antiviral activity and
better pharmacokinetics are in development (Dwyer et al., 2007;
Eggink et al., 2011).
Table 1
Antiviral activity (EC50 in mM) proﬁle of feglymycin (FGM) against cell-line-
adapted and several entry inhibitor resistant HIV strains in various cell types.
Cells Virus strains Tropism EC50 of FGM (mM)
MT-4 HIV-1 NL4.3 X4 0.9
MT-4 HIV-1 IIIB X4 3.2
MT-4 HIV-1 HE X4/R5 0.8
MT-4 HIV-2 ROD X4/R5 1.2
C8166 HIV-1 IIIB X4 1.9
PHA-activated PBMCsa HIV-1 NL4.3 X4 2.4
PHA-activated PBMCsa HIV-1 BaL R5 4.3
MDMb HIV-1 BaL R5 2.9
MT-4 HIV-1 NL4.3T20res X4 0.9
MT-4 HIV-1 NL4.32G12res X4 2.2
MT-4 HIV-1 NL4.3AMD3100res X4 2.4
a PHA-activated PBMCs: Phytohemagglutinin-activated peripheral blood
mononuclear cells.
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only important for treatment of HIV-infected persons; they are
also candidates for the prevention of HIV transmission. At the
moment, the development of antiviral compounds in mainly gel-
based formulations for microbicide application for vaginal/rectal
use is a thriving research area. Many challenges are still remain-
ing and it will be crucial to understand the exact mechanisms of
HIV infections through mucosal pathways (Hladik and Doncel,
2010). In recent years we and other research groups focused on
natural occurring peptides and proteins isolated from microor-
ganisms (e.g., Cyanobacteria and Streptomyces sp.) with anti-HIV
activity. For example, cyanovirin-N isolated from the cyanobac-
teria Nostoc ellipsosporum has a broad-spectrum anti-HIV activity
by targeting the N-linked glycans on gp120 (Boyd et al., 1997).
Recently, microvirin, closely related to cyanovirin-N, was isolated
from the cyanobacteria Microcystis aeruginosa and showed a
comparable antiviral activity, but a much higher safety proﬁle
(Huskens et al., 2010). Different kinds of Streptomyces-derived
peptides (e.g., the class of chloropeptins and siamycins) were
described as HIV entry/fusion inhibitors that demonstrated broad
anti-HIV activity (Constantine et al., 1995; Detlefsen et al., 1995;
Lin et al., 1996; Matsuzaki et al., 1997; Tsunakawa et al., 1995).
Here, we focus on a novel Streptomyces-derived peptide, called
feglymycin (FGM). FGM is a unique natural peptide of 13 amino
acids (MW, 1900.9 Da) originally isolated from Streptomyces sp.
DSM11171 (Ve´rtesy et al., 1999). It mainly contains unusual amino
acids such as 4-hydroxyphenylglycine (Hpg) and 3,5-dihydroxy-
phenylglycine (Dpg) (Fig. 1) and was recently fully chemically
synthesized by a sophisticated peptide synthesis strategy (Dettner
et al., 2009). X-ray crystallography has shown that FGM is able to
form a double stranded anti-parallel b-helical dimer (Bunko´czi
et al., 2005). Here, we investigated its anti-HIV activity proﬁle, its
mode of action and succeeded in generating in vitro an HIV-1
IIIBFGMres virus that appeared to have 2 unique mutations in the
viral gp120, not reported so far by any other known entry inhibitor.b MDM: monocyte-derived macrophages. Mean EC50s of at least 3 independent
experiments are shown.
Table 2
Broad-spectrum anti-HIV-1 activity (EC50 in mM) of feglymycin (FGM) against
clinical isolates representing different HIV-1 clades of group M.
UG273 R5 US2
R5
ETH2220 R5 UG270 X4 ID12
R5
RU570 R5
Clade A Clade B Clade C Clade D Clade A/E Clade G
FGM 2.8 0.5 1.8 6.7 3.1 5.2
Mean EC50s out of at least 2 individual PHA-activated PBMC donor experiments
are shown. Co-receptor tropism (R5/X4) of the viruses was determined as
described (Princen et al., 2004).Results
Broad-spectrum anti-HIV activity proﬁle of feglymycin
First, we evaluated the activity of feglymycin (FGM) against
cell line-adapted HIV-1 strains (NL4.3, IIIB, HE) and against the
HIV-2 strain ROD in susceptible CD4þ T cell lines (MT-4 and
C8166 cells). As shown in Table 1, FGM could inhibit infection of
these HIV strains with an EC50 in the lower mM-range (EC50: 0.8–
3.2 mM). Then, the anti-HIV activity of FGM was tested against
two HIV-1 strains and several HIV-1 clinical isolates from differ-
ent clades in PHA-activated PBMCs (or T cell blasts). We found
that FGM inhibited infection of the CXCR4-using (X4) NL4.3 and
the CCR5-using (R5) BaL HIV-1 strains in lower mM ranges (EC50s:Fig. 1. Structure of the 13mer pepti2.4–4.3 mM). Monocyte-derived macrophages (MDM) were also
protected against HIV-1 BaL infection by FGM (Table 1). FGM was
found active against clinical HIV-1 isolates representing members
of different viral clades (A–D, A/E and G) with mean EC50s varying
between 0.5 mM and 6.7 mM (Table 2).
The antiviral activity of FGM was also tested against in
vitro generated mutant HIV-1 strains: virus resistant to the gp41
fusion inhibitor T20 (HIV-1 NL4.3T20res), virus resistant to the
carbohydrate-binding anti-gp120 mAb 2G12 (HIV-1 NL4.32G12res)
and virus resistant to the CXCR4 antagonist AMD3100 (HIV-1
NL4.3AMD3100res). Comparable antiviral activity against these resis-
tant viruses was observed (EC50s: 0.9–2.4 mM; Table 1).
Next, the anti-HIV activity of FGM against an increasing series
of virus inputs of NL4.3 starting at 100 TCID50 (normally used in
our MT-4 antiviral assays) up to 5000 TCID50 was evaluated and
compared with the activity of the gp41 fusion inhibitor T20 and
the anti-gp120 mAb 2G12. Increasing the viral input up to 50-foldde antibiotic feglymycin (FGM).
Fig. 3. Time-of-drug addition experiments whereby MT-4 cells were infected with
X4 HIV-1 IIIB and FGM and various compounds with diverse well-described
antiviral inhibition modes were added at different time points in a range from 0 h
to 26 h post-infection.
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ingly, in a very consistent antiviral activity of FGM (only 4-fold
loss of activity). In contrast, T20 and 2G12 are quite sensitive to
the viral input and both agents lost completely their antiviral
activity when increasing the amount of virus input (Table 3).
Finally, we investigated if FGM has a broader antiviral activity
and tested it against dengue virus, hepatitis C virus and herpes
simplex virus type 1 and type 2. No activity for FGM was detected
against these viruses up to 26.3 mM (or 50 mg/ml) (data not shown).
Antiviral activity of alanine derivatives of feglymycin (ala-FGM)
To gain more insights in the position of crucial amino acids
involved in the anti-HIV activity of FGM various alanine deriva-
tives (ala-FGM) were synthesized. As shown in Fig. 2, the
substitution of L-aspartic acid at position 13 (L-Asp13) with a
neutral alanine (L-ala13-FGM) reduces the antiviral activity of
FGM 6.5-fold compared to native FGM. Other alanine substitu-
tions had no effect on the potency of the anti-HIV activity of FGM.
Feglymycin inhibits viral entry
To gain more insight in the mechanism of action of FGM, time-
of-drug addition (TOA) experiments were performed. Therefore,
MT-4 cells were infected with X4 HIV-1 IIIB and, at different time
points after infection (ranging from 0 h to 26 h and after 31 h),
FGM and several reference compounds were added. When a
compound is added after its antiviral target becomes operative,
no inhibition of viral replication will be observed. The polyanionic
binding/adsorption inhibitor dextran sulfate 8000 (DS8000;
421 mM or 100 mg/ml) lost its antiviral activity completely when
added 1 h after infection (Fig. 3). The CXCR4 antagonist AMD3100
(6 mM or 5 mg/ml) became completely ineffective when added
2 h after infection while reverse transcriptase inhibitors (RTI)
(e.g., nevirapine at 2 mg/ml or 7.5 mM) and protease inhibitors (PI)
(e.g., ritonavir at 2 mg/ml or 2.8 mM) kept their anti-HIV activityTable 3
Antiviral activity (EC50) of feglymycin (FGM), T20 and mAb 2G12 against a series
of viral inputs (TCID50) of HIV-1 NL4.3 in MT-4 cells.
Agents Viral input (TCID50) Fold decrease
a
100 500 1000 2500 5000
FGM (mM) 0.66 1.8 1.8 2.8 2.5 4
T20 (nM) 9.7 24.4 104 424 41113 4115
2G12 mAb (mg/ml) 0.51 2.1 3.4 420 420 439
a Fold decrease in antiviral activity calculated as: highest EC50/lowest EC50.
Mean EC50s of at least 2 independent experiments are shown.
Fig. 2. Antiviral activity of FGM alanine derivatives (ala-FGM) against X4 HIV-1
NL4.3. Mean EC50s7SEM out of at least two independent experiments are shown.4 h and 8 h post-infection, respectively (Fig. 3). The inhibitory
curve of FGM (tested at 100 mg/ml or 52.5 mM) coincides with
DS8000 and its antiviral activity disappeared when added 1 h
post-infection (Fig. 3). So these data suggests that FGM, like
dextran sulfate, acts as an early viral binding/adsorption inhibitor.
Inhibition of syncytia formation by feglymycin
CD4þ T cells cannot only be infected with free virions but also
very efﬁciently through cell-to-cell contacts with HIV-infected
CD4þ T cells. Consequently, we investigated if FGM was able to
inhibit the giant cell or syncytia formation in a co-cultivation assay
between persistently HIV-infected CD4þ T cells (HUT-78/IIIB cells)
and non-infected CD4þ target T cells (SupT1 cells). Fig. 4A shows a
light microscopic view of this assay and at 10.5 mM FGM comple-
tely inhibits the appearances of giant cells or syncytia. FGM
prevented the appearances of giant cells dose-dependently with a
mean EC50 of 5.4 mM (Fig. 4B). A comparable activity could be
observed for the CXCR4 antagonist AMD3100 (mean EC50: 4 mM)
and the gp41 fusion inhibitor T20 (mean EC50: 3 mM) (Fig. 4B).
Important to mention here is that the reference compounds
AMD3100 and T20 lost at least 1000-fold of their inhibitory activity
in these cell-to-cell viral transmission assays compared to their nM
activity reported by us and many other research groups in the
cell-free virus replication assays, whereas the antiviral activity of
FGM in this assay remained almost unchanged (Table 1). Another
included reference compound, the RTI tenofovir, showed as
expected no inhibitory effect at 50 mM (Fig. 4B). FGM also inhibited
syncytia formation when HUT-78/ROD (HIV-2) cells were co-cultured
with CD4þ T cells (mean EC50: 17.1 mM, Fig. 4C), although a 3-fold
loss of activity was observed compared to HUT-78/IIIB. However,
AMD3100 and T20 showed even no activity in the HIV-2 ROD
mediated co-cultivation assay (Fig. 4C).
Feglymycin interferes with CD4/gp120 interaction
Based on our TOA experiments and syncytia formation assays,
FGM inhibits an early step of the HIV replication cycle. The initial
Fig. 4. (A) Light microscopic view of the syncytia formation assay after 24 h of co-cultivation between persistently infected HUT-78/IIIB cells and non-infected CD4þ
SupT1 cells. Upper panels: (a) uninfected CD4þ SupT1 cells and (b) persistently infected HUT-78/IIIB cells. Lower panels: (c) giant cell formation after co-cultivation of
SupT1 cells with HUT-78/IIIB cells and (d) complete inhibition of syncytia formation in the presence of 10.5 mM FGM. Persistently infected HUT-78/IIIB (HIV-1) cells (B) and
HUT-78/ROD (HIV-2) cells (C) were co-cultivated with SupT1 cells in the presence of FGM, T20, AMD3100 and tenofovir. The bars represent the mean EC50-values7SEM.
Values 430 and 450 indicate an EC50 above 30 mM and 50 mM, respectively.
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and we investigated if FGM interferes with this process using a
sCD4/HIV-1 ELISA and a ﬂow cytometric cellular virus binding assay.
Human soluble CD4 (sCD4) was coated on a 96-well plate and
exposed to HIV-1 NL4.3 virus in the presence of test compounds.
FGM inhibited signiﬁcantly the binding of HIV-1 NL4.3 on the coated
CD4 with a mean EC50 of 4.4 mM (p¼0.002), as determined using
a sCD4/HIV-1 NL4.3 binding ELISA (Fig. 5A). The anti-CD4 mAb
RPA-T4 and the polyanionic compound PRO2000 were used as
control agents and inhibited also signiﬁcantly the binding of HIV-1
with CD4 with mean EC50s of 3.7 mg/ml for RPA-T4 and 0.33 mM
for PRO2000. As expected, the RTI tenofovir had no effect in this
sCD4/HIV-1 binding assay (EC50 410 mM).
In another experimental setup, we analyzed if FGM could
inhibit the binding of HIV-1 NL4.3 virus particles on cell surface
expressed CD4 using CD4þ SupT1 T cells (Fig. 5B). The amount of
virus bound on surface CD4 was detected using the anti-gp120
mAb 9205. In the presence of 10.5 mM FGM, virus binding was
abrogated for 74.5% (MFI of 12.2). The polyanionic compound,
PRO2000, here included as a control compound, inhibited HIV
binding by 94.3% (MFI of 6.1) at 4 mM. The CXCR4 antagonist
AMD3100 at 24.1 mM had no effect on virus binding to CD4þ
SupT1 T cells, as described previously (Schols et al., 1997)
(Fig. 5B). These data clearly demonstrate that FGM interferes
with the CD4/gp120 binding process.Kinetic analysis of the interaction of feglymycin with the viral
envelope protein gp120
A more quantitative way to determine if agents bind to the
HIV-1 envelope is the use of surface plasmon resonance (SPR)
technology (Hoorelbeke et al., 2010). In these experiments, binding
properties of FGM, D-ala6-FGM and L-ala13-FGM were evaluated
towards HIV-1 gp120 IIIB (X4) and to HIV-1 gp120 YU2 (R5). Both
ligands were covalently immobilized on CM5 sensor chips and
8200 RU and 9626 RU of density was obtained, respectively.
Two-fold serial dilution series covering a concentration range of
7.8–125 nM for FGM and D-ala6-FGM and 62.5 nM to 1000 nM for
L-ala13-FGM were applied to the gp120’s immobilized on a CM5
sensor chip. A 1:1 Langmuir kinetic ﬁt was applied to obtain the in
real time measured association rate constant ka (kon, on-rate) and
dissociation rate constant kd (koff, off-rate) and the afﬁnity constant
KD (ratio kd/ka) (Table 4; Fig. 6). As depicted in Fig. 6 (panels a and
b) and Table 4, FGM interacts potently to gp120 from the X4 strain
IIIB as well as the R5 strain YU2, with KD values of 6.170.2 nM and
2.270.3 nM, respectively. For D-ala6-FGM, a loss in KD value of
4-fold (X4 IIIB) and 6-fold (R5 YU2) was observed (Table 4; Fig. 6,
panels c and d). When we compared the peptide L-ala13-FGM with
native FGM, a 8-fold and 13-fold loss in KD was measured with
50.671.5 nM and 29.571.3 nM for HIV-1X4 IIIB and HIV-1 R5
YU2, respectively (Table 4; Fig. 6, panels e and f).
Fig. 5. FGM inhibits the binding of HIV-1 to CD4. (A) The binding of HIV-1 NL4.3 to sCD4 in the presence of FGM, anti-CD4 mAb RPA-T4 and PRO2000 was measured using
a sCD4/HIV-1 binding ELISA. The mean percentages7SEM of virus binding to sCD4 from at least 3 independent experiments are shown. Statistical signiﬁcance whereby
po0.05 is indicated by an asterisk (n) according to an unpaired T-test. (B) CD4þ SupT1 T cells were incubated with HIV-1 NL4.3 in the presence of 10.5 mM FGM, 4 mM
PRO2000 and 24.1 mM AMD3100, and virus binding was determined by ﬂow cytometry using the anti-gp120 mAb 9205. The blue histograms represent virus binding in the
absence of compound. Virus binding in the presence of FGM, PRO2000 and AMD3100 is shown in red, green and orange, respectively. The grey histograms show
background ﬂuorescence. The mean ﬂuorescence intensity (MFI) is shown. One representative experiment out of 2 is shown.
Table 4
Kinetic data for the interaction of FGM, D-ala6-FGM and L-ala13-FGM with
immobilized HIV-1 envelope proteins gp120 IIIB (X4) and gp120 YU2 (R5).
KD (nM) Kon (1/M.s) Koff (1/s)
FGM
gp120 IIIB (X4) 6.170.2 (4.9570.36) Eþ05 (3.0370.14) E-03
gp120 YU2 (R5) 2.270.3 (5.4770.72) Eþ05 (1.2070.05) E-03
D-ala6-FGM
gp120 IIIB (X4) 23.070.7 (7.9270.39) Eþ05 (1.8270.11) E-02
gp120 YU2 (R5) 12.170.9 (4.8970.44) Eþ04 (5.9270.36) E-03
L-ala13-FGM
gp120 IIIB (X4) 50.671.5 (6.5470.19) Eþ04 (3.3770.12) E-03
gp120 YU2 (R5) 29.571.3 (8.0370.30) Eþ04 (2.3770.09) E-03
KD, afﬁnity constant; kon, association rate constant; koff, dissociation rate constant.
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cells and on the subsequent virus transmission to CD4þ T cells
DC-SIGN on dendritic cells (DCs) plays also a pivotal role in the
transmission of HIV to CD4þ T cells (Hladik and McElrath, 2008). We
investigated if FGM prevented capture of HIV-1 (strain HE (X4/R5)) by
DC-SIGN using Raji cells transfected with DC-SIGN (Raji.DC-SIGNþ
cells). HIV-1 was pre-exposed to FGM, PRO2000 or HHA for 30min
before virus was administered to Raji.DC-SIGNþ cells (Fig. 7A). FGM
did not inhibit the binding of HIV-1 to DC-SIGN (EC50 45.3 mM)(p40.05). The polyanionic compound PRO2000 also lacked any
activity in this type of assay (EC50 42 mM) (p40.05). In contrast,
the plant lectin HHA inhibited signiﬁcantly the capture of HIV-1 on
DC-SIGN (mean EC50: 0.02 mM; p¼0.048), which is in agreement
with our previously published data on HHA and its inhibition of the
capture of X4 HIV-1 IIIB on Raji.DC-SIGNþ cells (Balzarini et al., 2007).
We also examined if FGM was able to inhibit giant cell formation
of virus-captured on DC-SIGNþ cells with CD4þ T cells. In the
absence of inhibitors, massive giant cells were formed 24–48 h post
co-cultivation (Fig. 7B, panels a–c). When FGMwas added at the start
of co-cultivation (and thus virus was already captured on Raji.DC-
SIGNþ cells), FGM was able to inhibit the subsequent syncytia
formation dose-dependently (mean EC50: 2.6070.03 mM; Fig. 7B,
panel d) comparable even to PRO2000 (mean EC50: 0.2370.03 mM).
HHA inhibited this process very efﬁciently (mean EC50: 43711 nM;
Fig. 7B, panel e). Thus, FGM inhibits virus binding and transmission
to CD4þ T cells, but does not inﬂuence the capture of virus to the
DC-SIGN receptor as such as this interaction is mainly carbohydrate-
dependent due to the high number of glycans on gp120.
Selection and mutation determination of feglymycin resistant HIV-1
IIIB (HIV-1 IIIBFGMres)
To decipher more in depth the mechanism of action of FGM, we
also investigated the development of HIV-1 resistance to FGM. We
therefore cultured X4 HIV-1 IIIB in the CD4þ T cell line C8166 in
Fig. 6. Kinetic analysis of the interactions of FGM, D-ala6-FGM and L-ala13-FGM with immobilized HIV-1 gp120 IIIB (panels a, c and e) and HIV-1 gp120 YU2 (panels b, d and
f). Serial 2-fold analyte dilutions covering a concentration range from 7.8 nM to 125 nM for FGM and D-ala6-FGM and 62.5 to 1000 nM for L-ala13-FGM were injected over
the surface of the immobilized gp120. The experimental data (colored curves) were ﬁt using the 1:1 binding model (black lines) to determine the kinetic parameters. The
data are a representative experiment out of three independent experiments.
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Subcultivations were performed on a weekly basis and when
strong virus-induced cytopathic effects (CPE) were observed micro-
scopically, FGM concentrations were slightly increased. At different
time points, virus was analyzed for changes in amino acids in the
env sequence and compared to the sequence of wild-type HIV-1
IIIB, which has been cultured in parallel but in the absence of
compound. It took between 20 and 30 passages of FGM selection to
gain an I153I/L mixed mutation in gp120, resulting in a 5-fold
decrease in antiviral activity. Eight passages later, the mixed
mutation became a pure mutation I153L and a novel mixed
mutation K457K/I arose, resulting in a 7-fold decrease in FGM
sensitivity. Finally, after 44 passages resistant virus (HIV-1
IIIBFGMres) was able to grow in the presence of 26.3 mM (or50 mg/ml) FGM. Interestingly, only two speciﬁc mutations in
gp120 of the resistant virus were observed, namely I153L in the
V2 loop region and K457I in the C5 loop region, and no amino acid
changes were observed in gp41.
Sensitivity of HIV-1 IIIBFGMres virus to various other classes of entry
inhibitors
The susceptibility of HIV-1 IIIBFGMres to various other EIs was
investigated and compared with their antiviral activity against
wild-type HIV-1 IIIB. As can be seen in Fig. 8B, the virus binding
inhibitor dextran sulfate (DS5000) and the CD4 down-modulating
compound, cyclotriazadisulfonamide (CADA), showed a 9-fold
and 415-fold decrease in antiviral activity, respectively. Other
Fig. 7. (A) Raji.DC-SIGNþ cells were incubated with HIV-1 HE in the presence of various concentrations FGM, PRO2000 and HHA. The effect on virus capture was
determined by the use of p24 HIV-1 Ag ELISA. Grey bars represent mean values7SEM. Statistical signiﬁcance whereby p o0.05 is indicated by an asterisk (n) according to
an unpaired T-test. (B) Microscopic view of syncytia formation after 24 h of co-cultivation of Raji.DC-SIGNþ cells pre-exposed to HIV-1 HE (Raji.DC-SIGNþ/HE) and CD4þ
C8166 T cells in the presence or absence of FGM and HHA. Upper panels: (a) C8166 T cells, (b) Raji.DC-SIGNþ/HE and (c) giant cell formation after co-cultivation of Raji.DC-
SIGNþ/HE and C8166 cells. Lower panels: protective effect of FGM (5.3 mM) when added only at the time of the co-cultivation (d) and protective effect of HHA (0.2 mM)
when given at the time of co-cultivation (e).
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mAb were equally active against the HIV-1 IIIBFGMres virus as the
wild-type HIV-1 IIIB. We evaluated several of the ala-scan pep-
tides such as L-ala5-FGM and D-ala6-FGM against HIV-1 IIIBFGMres
virus and observed that they also lost all antiviral activity (EC50
425 mM).Discussion
The entry process of HIV can still be considered as an attractive
target for ARV therapy. Each step of this process, binding/adsorp-
tion, (co)-receptor binding, membrane fusion and viral uncoating
can offer possibilities for the development of unique classes of EIs.
Here, we report the antiviral activity and mechanism of action
of the antibiotic peptide feglymycin (FGM). Due to its unique
structure, FGM can be considered as a prototype peptide of a
novel class inside the group of the viral EIs. FGM showed in vitro
a potent and consistent broad-spectrum ARV activity againstvarious HIV-1 clinical isolates representing different clades as
well as T cell line-adapted strains of HIV-1 and HIV-2 and this
independent of their co-receptor tropism (Tables 1 and 2).
In addition to the inhibition of infection of target CD4þ T cells
by cell-free virus, FGM was also able to prevent cell-to-cell virus
transmission between HIV-infected and non-infected CD4þ
T cells (Fig. 4). Human semen not only contains cell-free virus
but also cell-associated virus and evidence has accumulated that
seminal infected leucocytes can cross the vaginal barrier and
reach permissive target cells within the epithelium or submucosal
tissue (Coombs et al., 2003; D’Cruz and Uckun, 2006; Lederman
et al., 2006; Salle´ et al., 2010). Developing a microbicide blocking
this pathway of cell-to-cell HIV transmission can be of great
importance. In the VOICE (Vaginal and Oral Interventions to
Control the Epidemic) study, a large phase IIb clinical trial
designed to determine whether the tenofovir gel could prevent
transmission of HIV, no signiﬁcant protective effect was observed
(Celum, 2011). This lack of inhibition could be due to cell-
associated HIV transmission and a recent study showed that viral
Fig. 8. (A) Selection of HIV-1 IIIB FGM-resistant virus (IIIBFGMres). The HIV-1 IIIB virus was cultured in C8166 cells in the presence of sub-optimal concentrations of FGM,
and the drug concentration was increased when full CPE was observed. The time points where infected cell culture supernatant was taken for env gene characterization
and their appeared mutations are shown (arrows). (B) Cross-resistance proﬁle of HIV-1 IIIBFGMres to the entry inhibitors FGM, DS5000, PRO2000, HHA, T20, CADA,
AMD3100 and b12 mAb. The fold-increase in EC50s compared with wild-type HIV-1 IIIB virus is shown. One representative experiment out of 2 is shown.
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virus cell-to-cell transmission (Sigal et al., 2011). Because FGM
also inhibits HIV cell-to-cell transmission it could have a potential
advantage as microbicide candidate. No inhibitory effects of FGM
were observed when tested against other classes of enveloped
viruses such as herpes simplex virus type 1 and type 2 (HSV-1 and
HSV-2), dengue virus (DENV) and hepatitis C virus (HCV) (data
not shown). Thus, although limited broad-spectrum antiviral data
are available it demonstrates that FGM shows an antiviral activity
proﬁle with speciﬁcity for HIV.
To study the contribution of a speciﬁc amino acid to the
stability and function of FGM, alanine scanning mutagenesis
was performed. Substitution of L-aspartic acid at position 13
(L-Asp13) by alanine reduces the antiviral activity 7-fold
(Fig. 2). This decrease in antiviral activity of L-ala13-FGM com-
pared to native FGM is correlated with a 8-fold loss in afﬁnity
for gp120, measured as afﬁnity constant (KD) by SPR technology
(Table 4). The substitution of other amino acids has no effect on
the antiviral activity compared to the natural FGM. X-ray crystal-
lography showed that the linear 13mer amino acid peptide FGM
could also form dimers (Bunko´czi et al., 2005). L-Asp13 contributes
to the creation of stable hydrogen bridges in the helical dimer
structure of FGM. The change to L-Ala13 might result in loss ofstabilizing hydrogen bridges and a less distinct secondary struc-
ture of FGM in solution and as consequence a lower antiviral
activity. The substitution of L-Asp13 by an alanine also affects the
net charge of the peptide, which could lead to reduced electro-
static interactions with its target protein. In addition, nearly all
amino acids of FGM are repeated at least once in the sequence.
Therefore, the deletion of a single amino acid side chain may be
well tolerated regarding the antiretroviral activity of this peptide.
This should enable the synthesis of structurally less complex FGM
derivatives with similar or even increased biological activity.
As shown here FGM acts at a very early step in the virus
replication cycle, the viral binding/adsorption process. Based on
time-of-drug addition experiments, FGM interferes with this
entry process at the same moment as the polyanionic class of
compounds dextran sulfate and PRO2000, but earlier then the
CXCR4 antagonist AMD3100. So, we could already assume that
FGM inhibits virus binding to the CD4 receptor and that it did not
interact with the HIV fusion-uncoating process. When we inves-
tigated virus attachment in more detail, FGM acted in a compar-
able manner as the anti-CD4 mAb RPA-T4 and PRO2000 in the
sCD4/HIV-1 binding ELISA and in a virus binding assay on CD4þ
T cells measured by ﬂow cytometry (Fig. 5). Additionally, when
we used SPR technology whereby gp120 was immobilized on a
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blocked by FGM (data not shown). RPA-T4 mAb targets the D1
region of the cellular CD4 receptor and blocked, as FGM, the
binding of HIV-1 to human sCD4. However, when we incubated
T cells with FGM, no down-regulating effect on the CD4 receptor
was observed, in contrast to RPA-T4 and the CD4 down-
modulating agent CADA (data not shown and Vermeire et al.,
2009). Also, no direct interaction of FGM with the HIV cellular co-
receptors was measured as FGM could not block the intracellular
Ca2þ signaling induced by CXCL12 and CCL3L1 in CXCR4- and
CCR5-transfected cell lines, respectively (data on ﬁle).
PRO2000 is described to be an inhibitor of CD4/gp120 binding
by interacting with gp120 and CD4 (Rusconi et al., 1996; Scordi-
Bello et al., 2005). FGM could also inhibit the binding of HIV to
CD4þ T cells. However, more potent inhibition of the virus
binding with PRO2000 was measured: 94.3% inhibition with
4 mM PRO2000 and 74.5% inhibition with FGM at 10.5 mM. The
stronger antiviral activity of PRO2000 in HIV replication assays
and the surface plasmon resonance (SPR) studies showed that
PRO2000 interacted with high afﬁnity on (soluble) gp120 of X4
and R5 viruses (KD: 2–3 nM) (Scordi-Bello et al., 2005 and our
own unpublished data). When SPR-based kinetic analysis was
performed with FGM for binding to gp120, comparable afﬁnity
constants were recorded with mean KD-values of 6.1 nM for X4
gp120 IIIB and 2.2 nM for R5 gp120 YU2 (Fig. 6 and Table 4).
To get more insight in the mechanism of action of FGM against
HIV, an FGM-resistant virus was selected (Fig. 8). Finally, at passage
44 of HIV-1-infected cell cultures, two speciﬁc mutations were
found: I153L and K457I, resulting in a 14-fold increase in the
EC50-value of FGM (Table 1 and Fig. 8). Mutation I153L is located in
the V2 region of gp120, which is localized proximal to the CD4
binding domain and is also a part of the bridging sheet (Kwong
et al., 1998; Zolla-Pazner, 2004). Additionally, Wu et al. (2009)
showed that certain mutations inside the V1/2 loop can inﬂuence
the ﬂexibility of gp120 and thus the binding of the mAb b12,
recognizing the CD4 binding site in the C4 region on gp120. K457I
is located in the C5 region, near the CD4 binding site, and can
be involved in stabilizing the CD4 binding conformation site
on gp120. The small molecule, BMS378806, was described as a
speciﬁc CD4/gp120 inhibitor by targeting gp120 and the
BMS378806-resistant virus contained also two mutations in
gp120 (M426L in the C4 region and M475I in the C5 region) (Lin
et al., 2003; Wang et al., 2004). The observation that the resistance
mutation K457I for FGM is in the same region as the M475I
BMS378806 mutation is another indication for its antiviral mode
of action. These two mutations in gp120 are unique for FGM and no
cross-resistance was observed with the class of CBAs such as HHA
and 2G12 mAb. This was expected, as FGM does not target the
N-glycans present on gp120, as it does not inhibit HIV binding to
DC-SIGNþ cells and that it kept its antiviral activity against the
HIV-1 NL4.32G12res virus (Table 1). The CBA class of HIV inhibitors
have also activity against other classes of viruses such as DENV and
HCV (Alen et al., 2009; Bertaux et al., 2007). As already mentioned
and in contrast with the CBAs, FGM was not able to inhibit the
capture of virions to DC-SIGN (Fig. 7). In vitro studies have shown
that polyanionic compounds such as PRO2000 and dextran sulfate
also do not inhibit the capture of HIV to DC-SIGN, while the CBAs
potently inhibited this process (Balzarini et al., 2007). Interestingly,
approximately a 9-fold increase in EC50 was observed for the
polyanionic compound dextran sulfate (DS5000) against the HIV-1
IIIBFGMres virus. Dextran sulfate resistant virus showed 7 muta-
tions throughout various regions in gp120 (such as V1/2) (Este´
et al., 1997) and can be considered as a much more aspeciﬁc anti-
HIV compound compared to BMS378806. The appearance of
DS5000 cross-resistance further suggests that FGM acts as virus
binding/adsorption inhibitor. The lack of cross-resistance with thepolyanionic compound PRO2000 can be explained by the addi-
tional mechanisms of action of PRO2000. Our research group
showed earlier that PRO2000 could also interact with the CXCR4
chemokine receptor while DS5000 does not (Huskens et al., 2009).
Many other described anti-HIV peptides targeting the entry
process are mainly active not at binding but at the fusion event.
The gp41 fusion inhibitor T20 was equally active against the HIV-1
IIIBFGMres virus as the wild-type virus. Also, no difference in
antiviral activity of FGM was noticed against HIV-1 NL4.3T20res
virus (Table 1). FGM and T20 interfere with different stages of the
HIV entry process and the most commonly observed HIV-1 muta-
tions for resistance to T20 are located in the HR1 region of gp41 at
positions 36 (G36S) and 38 (V38M/A), although changes in gp120
also can appear and inﬂuence the activity of T20 (Matthews et al.,
2004). If we compare FGM to an earlier described Streptomyces-
derived peptide, siamycin I, a complete different mechanism of
antiviral action is observed. Siamycin I is a tricyclic peptide
containing 21 amino acids that acts as fusion inhibitor and does
not inhibit the CD4/gp120 interaction (Lin et al., 1996 and our
unpublished data). As FGM, siamycin I inhibited viral replication in
the cell-free virus assay as well as giant cell formation in a co-
cultivation assay. The siamycin-resistant virus showed 6 amino
acid changes throughout gp120 and gp41 (Lin et al., 1996). Virus-
inhibitory peptide, or VIRIP, is also a peptide and it represents a
small piece of a larger protein normally found in our blood, alpha1-
anti-trypsin. This peptide also differs in its mode of action with
FGM as VIRIP blocks HIV infection by binding to the viral protein
gp41 and preventing fusion between the viral envelope and the cell
membrane, as T20 does (Mu¨nch et al., 2007).
AMD3100 targets speciﬁcally the cellular CXC-chemokine
CXCR4 receptor (Schols et al., 1997) and the HIV-1 IIIBFGMres virus
was still equally sensitive to AMD3100 (Fig. 8). The HIV-1
NL4.3AMD3100res virus also showed multiple mutations in various
regions in gp120 (De Vreese et al., 1996), however, no loss of
antiviral activity was observed when FGM was tested against this
HIV-1 NL4.3AMD3100res (Table 1). Somewhat surprisingly, the CD4
down-modulating agent CADA lost its antiviral activity against
HIV-1 IIIBFGMres virus.
During sexual intercourse, vaginal/cervical micro-abrasions
play a pivotal role in the transmission of HIV. DC-SIGNþ DCs in
the mucosal tissues play an important role in the defense against
pathogens, however several viruses (such as HIV) can hijack the
attachment receptor DC-SIGN on DCs and efﬁciently transmit HIV
towards naive T cells in the lymph nodes (Hladik and McElrath,
2008). The role of DC-SIGN in the transmission of HIV remains
still controversial. Granelli-Piperno et al. have shown that
DC-SIGN is not required for transmission of HIV and subsequently
stimulation of CD4þ T cells (Granelli-Piperno et al., 2005), while
Geijtenbeek et al. (2000) described that the presence of DC-SIGN
increased HIV infection . While FGM was not able to inhibit virus
capture to DC-SIGN, it inhibited subsequent viral transmission
and infection of CD4þ T cells. The effect of FGM in the transmis-
sion assay can be explained also by efﬁciently inhibiting the trans-
infection of HIV to the T cells by interfering with the gp120
attachment on the cellular CD4 receptor and this further strength-
ens its potential as microbicide candidate (Wu and KewalRamani,
2006). Despite a lot of intensive research and several clinical
trials, the ideal and reasonable priced microbicide still has to be
developed. Manufacturing T20 is a very complicated process of
more than 100 steps, which is reﬂected in a high production price
(Bray, 2003). For FGM, it is possible to use the bacterial producer
in a fermentative process for large-scale production. Likewise,
fermentative processes are widespread in the synthesis of anti-
biotics, e.g., tetracycline, erythromycin, vancomycin and penicillin
are all natural products that are gained from fermentative
processes (Elander, 2003).
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themselves from HIV infection by using an effective vaginal/rectal
microbicide gel. An important feature for further microbicide
application and development is the observed consistent anti-
HIV activity of FGM regardless of viral input (Table 3). No
signiﬁcant decrease in activity was noticed when the viral input
was even up to 50-fold higher, while the gp41 fusion inhibitor
T20 and the carbohydrate-binding gp120 mAb 2G12 lost com-
pletely their activity with higher viral input. This shows that FGM
interacts completely different with the viral envelope protein
compared to other described entry inhibitors. The lack in the
titration of FGM inhibition could suggest a non-saturable effect.
In conclusion, FGM is to our knowledge the only peptide
described so far that inhibits the gp120/CD4 interaction, while
many other peptide entry inhibitors (e.g., siamycin, T20, VIRIP
and CBAs) do not. The results of the alanine scan indicate that
FGM might also serve as a lead-structure for further development
of even smaller inhibitory peptides against HIV.Materials and methods
Test compounds/peptides
Feglymycin (FGM) and its alanine derivatives (ala-FGM) were
synthesized as described previously (Dettner et al., 2009). The CXCR4
antagonist AMD3100 was obtained from Dr. G. Bridger (at that time
at AnorMED, Langley, Canada). Enfuvirtide (T20) was a kind gift
from Dr. E. Van Wijngaerden (UZ Leuven, Belgium). Nevirapine and
ritonavir were ordered from Boehringer Ingelheim GmbH (Germany)
and Abbot (USA), respectively. Tenofovir was a gift from Dr. A. Holy´
(Prague, Czech Republic). The polyanionic compound PRO2000 was
obtained from Dr. A. Profy (Indevus Pharmaceuticals Inc., Lexington,
MA, USA) and the dextran sulfates MW 5000 and 8000 were ordered
from Sigma-Aldrich (Bornem, Belgium). HHA was ordered from
E.Y. Laboratories (San Mateo, CA, USA). CADA was a kind gift from
Dr. T.W. Bell (University of Nevada, Reno, Nevada). The anti-gp120
mAbs b12 and 2G12 were purchased by Polymun Scientiﬁc (Vienna,
Austria). The anti-CD4 mAb RPA-T4 was ordered by eBioscience (San
Diego, CA, USA).
Cell lines and cell cultures
MT-4 cells were obtained from Dr. L. Montagnier (at that time
at the Pasteur Institute, Paris, France), while the HUT-78, SupT1
and C8166 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). HUT-78 cells were infected
with HIV-1 IIIB and HIV-2 ROD and cultured for 2–3 weeks to
become persistently infected. Raji.DC-SIGNþ cells were a gift
from Dr. L. Burleigh (Pasteur Institute, Paris, France). All cell lines
were cultured in RPMI-1640 medium (Invitrogen, Merelbeke,
Belgium) supplemented with 10% fetal calf serum (FCS; Hyclone,
Logan, Utah) and 1% L-glutamine (Invitrogen).
Peripheral blood mononuclear cells (PBMCs) were isolated out
of buffy coats from healthy donors, derived from the blood
transfusion Center (UZ Leuven, Belgium), by density gradient
centrifugation. PBMCs were cultured in RPMI-1640 supplemented
with 10% FCS, 1% L-glutamine and stimulated with 2 mg/ml PHA
(Sigma-Aldrich) for 3 day at 37 1C before further use in antiviral
assays as PHA-activated PBMCs (T cell blasts).
Monocyte-derived macrophages (MDM) were prepared as
follows: PBMCs (2106 cells/ml) were seeded in a 48-well plate
(Costar 3548) in 1 ml RPMI-1640 medium with 10% FCS and
incubated for 1 week at 37 1C. Afterwards, the non-adherent cells
were gently mixed and removed from the adherent cell layer. The
cells were carefully washed and this washing step was repeatedafter 6 day of incubation at 37 1C. The adherent cells were then
infected with HIV-1 R5 BaL.
Viruses
X4 HIV-1 strains NL4.3 and IIIB were obtained from the NIAID
AIDS reagent program (Bethesda, MD). R5 HIV-1 BaL and HIV-2
ROD were obtained from the Medical Research Council (MRC,
London, UK). The dual-tropic (R5/X4) strain HE was originally
isolated from a Belgian AIDS patient and later on cultured in
various T cell lines (Pauwels et al., 1990). The clinical isolates
were kindly provided by Dr. J. L. Lathey (then at BBI Biotech
Research Laboratories, Gaitherburg, MD). Their co-receptor usage
was determined by us using the astroglioma U87.CD4.CXCR4 and
U87.CD4.CCR5 transfected cells.
The NL4.3 strains resistant to AMD3100, 2G12 mAb and T20 were
generated earlier (Huskens et al., 2007; De Vreese et al., 1996).
Antiviral replication assays
The antiretroviral assays in MT-4 cells and PBMCs have been
described in detail earlier (Vermeire et al., 2004). Brieﬂy, MT-4
(50 ml; 1106 cells/ml) or C8166 cells (50 ml; 2105 cells/ml)
were pre-incubated for 30 min at 37 1C with test compounds
(100 ml) in a 96-well plate (Falcon). Next, virus (NL4.3, IIIB, HE,
ROD) was added according to the TCID50 of the viral stock.
Cytopathic effect (CPE) was scored microscopically 5 day post-
infection, and EC50-values were determined using the MTS/PES
method (Vermeire et al., 2004). PHA-stimulated PBMCs (200 ml;
5105 cells/ml) were also pre-incubated for 30 min with test
compounds (250 ml) in the presence of 2 ng/ml IL-2 (Roche Applied
Science) and afterwards 1000 pg p24/ml virus (50 ml) was given. At
days 3 and 6 post-infection, again 2 ng/ml IL-2 was added. Ten
days post-infection, supernatant was collected for p24 Ag HIV-1
ELISA (Perkin Elmer, Zaventem, Belgium) according to manufac-
turers’ guidelines. The MDM cells were seeded in a 48-well plate in
1 ml medium. After removal of 800 ml of cell culture medium
(RPMI-1640 supplemented with 10% FCS and 1% L-glutamine),
250 ml of test compounds was added. Each concentration was
tested in triplicate. After an incubation of 30 min at 37 1C, 1000
pg/well of HIV-1 R5 BaL was added. Three weeks post-infection,
supernatant was collected and evaluated by p24 HIV-1 Ag ELISA.
Cell-cell co-cultivation assays
Various concentrations of test compounds (100 ml) were added
in a 96-well plate along with SupT1 cells (1105 cells/50 ml).
Next, 50 ml of HUT-78 cells persistently infected with either HIV-1
IIIB (HUT-78/IIIB) or HIV-2 ROD (HUT-78/ROD) were seeded at
the same amount. Syncytia formation was scored microscopically
20–24 h post-co-cultivation at 37 1C.
Time-of-drug addition studies
MT-4 cells (1106 cells/ml) were infected with HIV-1 IIIB at a
multiplicity of infection (MOI) of 0.5. Test compounds were added
at different time points in a range from 0 h to 26 h post-infection.
After 31 h, virus production was measured using p24 HIV-1 Ag
ELISA. The reference compounds were added at 100 times their
EC50, as obtained in MT-4 cells by the MTS/PES assay.
HIV-1 capture by Raji.DC-SIGNþ cells and subsequent transmission
to uninfected CD4þ target T cells
Raji.DC-SIGNþ cells (200 ml; 2.5106 cells/ml) were added to
a 30 min pre-incubated mixture at 37 1C of 100 ml HIV-1 HE
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tions of test compounds. After 2 h incubation at 37 1C, samples
were extensively washed with PBS and lyzed with triton-X100/PBS
buffer for p24 Ag detection by p24 HIV-1 Ag ELISA. Raji.DC-SIGNþ
cells were exposed to HIV-1 HE for 1 h at 37 1C. Meanwhile, 100 ml
of various concentrations of test compounds were added in a
96-well plate and pre-incubated with C8166 target T cells (50 ml;
2106 cells/ml). Unbound virus was removed by extensive wash-
ing and the same amount of Raji.DC-SIGNþ cells were added to the
96-well plate, already containing the C8166 cells. After 24 h, giant
cell formation was scored microscopically.
Soluble CD4/HIV-1 binding ELISA
Human soluble CD4 (sCD4; ImmunoDiagnostics, Inc., Woburn,
MA, USA) (25 ng/ml) was coated on 96-well Maxi-Sorp plates
(Fisher Scientiﬁc, Erembodegem, Belgium) using freshly prepared
50 mM carbonate buffer pH 9.6 for 1 h at 37 1C. Subsequently,
PBST (phosphate buffered saline, pH 7.4 with 0.05% Tween-20)
containing 2% milk powder was used overnight at 4 1C to block
the wells. The next day, HIV-1 NL4.3 was pre-treated with
500 mM aldrithiol-2 (Sigma-Aldrich) for 1 h at 37 1C. The coated
plates were washed 3 times with PBST before various concentra-
tions of test compounds and virus (5104 pg p24/ml) were
added. After 1 h incubation at 37 1C, the plates were extensively
washed with PBST and incubated for 1 h at room temperature
with D7324, a primary sheep anti-gp120 antibody (Aalto Bio
Reagents, Dublin, Ireland). After washing, a secondary alkaline
phosphatase-labeled donkey-anti-sheep antibody (DaS-AP;
Sigma-Aldrich) was incubated under the same conditions. Color
development occurred after washing and substrate solution
addition (SigmaFASTTM p-nitrophenyl-phosphate (PNPP; Sigma-
Aldrich)). Absorbance was determined at 405/620 nm using the
Saﬁre 2 plate reader (Tecan, Ma¨nnedorf, Switzerland).
Surface plasmon resonance (SPR) analysis
Recombinant gp120 proteins from X4 HIV-1 (IIIB) and R5 HIV-1
(YU2) (ImmunoDiagnostics Inc., Woburn, MA) were covalently
immobilized on the carboxymethylated dextran matrix of a CM5
sensor chip in 10 mM sodium acetate, pH 4.0, using standard
amine coupling chemistry. The exact chip densities are given in the
Results section. A reference ﬂow cell was used as a control for non-
speciﬁc binding and refractive index changes. All interaction
studies were performed at 25 1C on a Biacore T200 instrument
(GE Healthcare, Uppsala, Sweden). The test agents were serially
diluted in HBS-P (10 mM HEPES, 150 mM NaCl and 0.05% surfac-
tant P20; pH 7.4), supplemented with 10 mM Ca2þ , covering a
concentration range between 62.5 nM and 500 nM by using two-
fold dilution steps. Samples were injected for 2 min at a ﬂow rate
of 45 ml/min and the dissociation was followed for 5 min. One
duplicate sample and several buffer blanks were used as a positive
control and for double referencing, respectively. The CM5 sensor
chip surface was regenerated with 1 injection of 50 mM NaOH. The
experimental data were ﬁt using the 1:1 binding model (Biacore
T200 Evaluation software 1.0) to determine the binding kinetics.
HIV-1 NL4.3 binding to CD4þ SupT1 cells
First, 200 ml of test compounds were diluted in a 15 ml
polypropylene tube (Falcon). Subsequently, CD4þ SupT1 cells
(2.5106 cells/ml) were added at an equal volume. Then, high
amounts of HIV-1 NL4.3 stock (100 ml; 2.8106 pg p24/ml) was
given and incubated at room temperature for 2 h. After extensive
washing with PBS/FCS2% (PBS supplemented with 2% FCS), the
samples were incubated with 200 ml anti-gp120 mAb (NEA-9205,NEN, Boston, MA) (500 ng/ml 9205 diluted in PBS/FCS2%) solution
for 30 min at 4 1C. A secondary goat-anti-mouse PE labeled (GaM-
PE; Invitrogen) antibody (1/100 diluted) was added after washing
and incubated for 30 min at 4 1C. As a control for aspeciﬁc
background staining, the cells were stained with GaM-PE only.
Finally, the samples were washed and ﬁxed with 1% p-formalde-
hyde solution and virus binding was determined by ﬂow cyto-
metry (FACSCalibur, BD Biosciences) and analyzed using
CellQuest (BD Biosciences) and Flowjo software (Tree Star, San
Carlos, CA). Virus binding is expressed in mean ﬂuorescence
intensity (MFI) values. Percentage inhibition was determined
after subtracting the MFI of the background staining.
Selection of FGM resistant HIV-1 IIIB (IIIBFGMres)
HIV-1 IIIB was added to C8166 cells (2.5105 cells/ml) in 24-
well plates in the presence of 0.5 mM of FGM. Every 5 day, viral
replication was scored microscopically and when full CPE was
observed, replicated virus was passaged to uninfected C8166 T
cells in the presence of increasing FGM concentrations. After 44
passages, virus (HIV-1 IIIBFGMres) was collected that was able to
grow in the presence of 50 mg/ml (or 26.3 mM) FGM.
Genotyping of the HIV-1 env region
Viral RNA was extracted from cell culture supernatants using
QIAamp Viral RNAminikit (Qiagen, Hilden, Germany). The genotyping
of the gp120 and gp41 genes were determined as described earlier
(Van Laethem et al., 2005).Acknowledgments
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